HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Lantadene B

HCID 15560077
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
467-82-3
Standard SMILES
CC(C)=CC(=O)O[C@@H]1CC(C)(C)C[C@H]2C3=CC[C@@H]4[C@@]5(C)CCC(=O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@@]12C(=O)O
InChIKey
VYPAPFHUHDWCBI-QQAPFUPGSA-N
Molecular formula
C35H52O5
Average molar mass
552.8 g/mol
Monoisotopic mass
552.38147475

Overview

lantadene b has been reported in Combretum sundaicum, Varronia multispicata, and Lantana camara with data available.

Names & identifiers

Preferred name
Lantadene B
IUPAC
(4R,4aS,6aR,6aS,6bR,8aR,12aR,14bS)-2,2,6a,6b,9,9,12a-heptamethyl-4-(3-methylbut-2-enoyloxy)-10-oxo-3,4,5,6,6a,7,8,8a,11,12,13,14b-dodecahydro-1H-picene-4a-carboxylic acid
English name
lantadene B
Molecular formula
C35H52O5
Molecular weight
552.78

Names & synonyms

Lantadene B467-82-3A54682CY7GDTXSID60196913Olean-12-en-28-oic acid, 22-beta-hydroxy-3-oxo-, 3-methylcrotonate22-((3-Methyl-1-oxo-2-butenyl)oxy)-3-oxo-olean-12-en-28-oic acid, (22,beta)-Olean-12-en-28-oic acid, 22-((3-methyl-1-oxo-2-butenyl)oxy)-3-oxo-, (22beta)-RefChem:798450DTXCID00119404(4R,4aS,6aR,6aS,6bR,8aR,12aR,14bS)-2,2,6a,6b,9,9,12a-heptamethyl-4-(3-methylbut-2-enoyloxy)-10-oxo-3,4,5,6,6a,7,8,8a,11,12,13,14b-dodecahydro-1H-picene-4a-carboxylic acidUNII-A54682CY7GHSDB 3504
Show more names
22β-[(3-Methyl-1-oxo-2-butenyl)oxy]-3-oxoolean-12-en-28-oic acidOlean-12-en-28-oic acid, 22-[(3-methyl-1-oxo-2-buten-1-yl)oxy]-3-oxo-, (22β)-
BRN 30781443-10-00-04397 (Beilstein Handbook Reference)orb1696618CHEMBL2413418AKOS040752412(4R,4aS,6aS,6bR,8aR,12aR,12bR,14bS)-2,2,6a,6b,9,9,12a-heptamethyl-4-((3-methylbut-2-enoyl)oxy)-10-oxo-1,3,4,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-octadecahydropicene-4a(2H)-carboxylic acidNS00094749T32563

Properties

Computed structural properties

XLogP
8
Topological polar surface area
80.7 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
5
Rotatable bonds
4
Heavy atoms
40
Formal charge
0
Complexity
1,190

Experimental & physicochemical properties

Chemical ClassesBiological Agents -> Plant Toxins
Color/FormCrystals from ethanol
Melting Point302 °C

Physicochemical properties

Boiling point
626.3 · 626.3±55.0 °C(Predicted)
Density
1.12 · 1.12±0.1 g/cm3(Predicted)
pka
4.11 · 4.11±0.70(Predicted)
FDA UNII
54682 CY7G · A54682CY7G
Comptox DTXSID
60196913 · DTXSID60196913
Hazardous Substances Data
467 · 467-82-3(Hazardous Substances Data)

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Hazard information

Hazards Summary · 1 item

Emergency treatment: Plants- lantana; Poisoning occurs when children eat the unripe berries that contain an anticholinergic poison. Jaundice is reported in poisoned grazing animals but not in human cases; Poisoned children have vomiting, diarrhea, dyspnea, dilated pupils, ataxia, weakness, and coma. [HSDB]

Safety & protection

Disposal Methods · 1 item

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

Toxicology

Adverse EffectsNeurotoxin - Other CNS neurotoxin
Natural Pollution SourcesLANTADENE B IS A TOXIC COMPONENT OF LANTANA CAMARA.
Non-Human Toxicity Excerpts · 5 items

/LABORATORY ANIMALS: Acute Exposure/ Oral administration of lantana (Lantana camara var. aculeata) leaf powder to guinea pigs at a dose of 6 g/ kg body weight elicited cholestasis. The animals were euthanized 48 hr after dosing.

/LABORATORY ANIMALS: Acute Exposure/ A toxin fraction was obtained from Lantana camara L (red variety) leaves by batch extraction and column chromatography on silica gel (60-120 mesh). The main constituents of the toxin preparation were lantadene A and lantadene B and it was devoid of reduced lantadene A. Oral administration (125 mg/kg bwt) of the toxin to male and female guinea pigs caused icterus and photosensitization within 48 hr. All the affected animals had hepatomegaly and significant increases in conjugated and unconjugated bilirubin in blood plasma. The intoxicated animals of either sex had marked increases in acid phosphatase activity which was inhibited 45.77% and 49.35% by 1 mM tartrate in male and female animals respectively. The corresponding inhibition of acid phosphatase activity in control male and female guinea pigs was 15.91% and 20.33% respectively.

Chemistry & industry

Pharmacology

Mechanism of Action · 1 item

Sheep poisoned with 600 g fresh Lantana camara showed inhibited gall bladder contraction after iv administration of the gall bladder stimulants cholecystokinin, pentagastrin, pilocarpine nitrate, and HCl 4 days after the poisoning. Gall bladder responses occurring after the stimulant administration were so few that the effect of lantana on the response duration could not be measured. Lantadene A inhibited the cholecystokinin-induced contractions in gall bladder strips. Gall bladder paralysis, which may occur during lantana poisoning, maybe due to the accumulation of bile acids.

Absorption, Distribution and Excretion · 1 item

/Guinea pig/ liver homogenates, bile, gall bladder, blood, urine, contents of gastrointestinal tract (GIT) and feces were analysed for the principal hepatotoxin in lantana leaves viz. lantadene A (LA), its congeners and biotransformation products, using high performance liquid chromatographic technique. Lantadenes could not be detected in liver, bile, gall bladder, blood and urine samples. LA and lantadene B (LB), their derivatives reduced lantadene A (RLA), reduced lantadene B (RLB) and two unidentified metabolites could be detected in the contents of lower GIT and faeces. In vitro incubation of lantana leaf powder with guinea pig caecal contents under anaerobic conditions elicited biotransformation of LA and LB to RLA and RLB, respectively. On the other hand, incubation of lantana leaf powder with cattle rumen liquor under anaerobic conditions did not elicit biotransformation of lantadenes.

Uses & manufacturing

Uses · 2 items

Toxic constituent of the tropical plant Lantana camara; [HSDB]

The Lantana camara triterpene acid lantadene B ingested at high dosage causes jaundice, photosensitization, and kidney and liver lesions in sheep.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Database identifiers

CAS
467-82-3
PubChem CID
15560077
DTXSID
DTXSID60196913
ChEMBL
CHEMBL2413418、CHEMBL555367
UNII
A54682CY7G
Nikkaji
J12.095B

/LABORATORY ANIMALS: Acute Exposure/ Oral or intraruminal administration of the Lantana camara triterpene acid lantadene B (200-300 mg/kg) to sheep caused jaundice, photosensitization, and kidney and liver lesions. Lantadene A was most toxic to sheep, followed by reduced lantadene A, while lantadene B was toxic only at high dosages.

/LABORATORY ANIMALS: Acute Exposure/ Lantana intoxication of Guinea pig inhibited lipid peroxidation in different tissues in the order: adrenals greater than liver greater than kidneys greater than heart greater than lungs greater than testes greater than brain. Lantadene A caused just marginal inhibition of lipid peroxidation in Guinea pig liver homogenates.

For more Non-Human Toxicity Excerpts (Complete) data for LANTADENE B (9 total), please visit the HSDB record page.

Antidote and Emergency Treatment · 3 items

/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/

/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/

/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/

Safety data

Hazardous Substances Data
467-82-3(Hazardous Substances Data)